Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: A UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Journal of Human Hypertension

Volumn 20, Issue 1, 2006, Pages 51-58

  McInnes, Gordon ^a   Burke, T A ^b   Carides, G ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cost effectiveness; Hypertension; Losartan; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; LOSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; INDIVIDUALITY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL RATE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33644962498     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001939     Document Type: Article

References (41)

1. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442.
2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
3. Wolfe PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-318.
4. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers DG, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
5. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-1151.
6. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. BMJ 1985; 291: 97-104.
7. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 1992; 304: 405-412.
8. Heart disease and stroke statistics - 2005 update. American Heart Association, accessed from http://www.americanheart.org/ presenter.jhtml?identifier=3000090.
9. Beech R, Rudd AG, Tilling K, Wolfe CD. Economic consequences of early inpatient discharge to community-based rehabilitation for stroke in an inner-London teaching hospital. Stroke 1999; 30: 729-735.
10. Claesson L, Gosman-Hedstrom G, Johannesson M, Fagerberg B, Blomstrand C. Resource utilization and costs of stroke unit care integrated in a care continuum: A 1-year controlled, prospective, randomized study in elderly patients: The Goteborg 70+ Stroke Study. Stroke 2000; 31: 2569-2577.
11. Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology 2001; 57: 305-314.
12. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; 21(Suppl 1): 43-50.
13. Ghatnekar O, Persson U, Glader EL, Terent A. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004; 20: 375-380.
14. Caro JJ, Huybrechts KF. Stroke treatment economic model (STEM): predicting long-term costs from functional status. Stroke 1999; 30: 2574-2579.
15. Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RA, McNeil JJ et al. Lifetime cost of stroke subtypes in Australia. Findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003; 34: 2502-2507.
16. Terent A, Marke LA, Asplund K, Norrving B, Johsson E, Wester PO. Costs of stroke in Sweden. A national perspective. Stroke 1994; 25: 2363-2369.
17. Bergman L, van der Meulen JHP, Limburg M, Habbema JDF. Costs of medical care after first-ever stroke in the Netherlands. Stroke 1995; 26: 1830-1836.
18. Active Ageing. A policy framework. World Health Organization. WHO/NMH/ NPH/02.8.
19. IMS Market Trend Analysis (MTA) for UK Retail and Hospital as assessed by MSD using IMS Health Disease Analyzer-Mediplus data, January 2005.
20. Caro J, Klittich W, McGuire A, Ford I, Norrie J, Pettitt D et al. The West of Scotland coronary prevention study: Economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-1582.
21. World Health Organization. Life tables and methods: Life tables for the United Kingdom 2000. http://www.who.int/countries/gbr/en/.
22. Carides GW, Heyse JF, Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 2000; 1: 299-313.
23. Loader C. Local Regression and Likelihood. Springer-Verlag: New York, 1999.
24. National Statistics. Consumer price indices - December 2003. 1-20-2004.
25. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
26. Efron BTR. An Introduction to the Bootstrap. Chapman and Hall: New York, 1993.
27. HM Treasury. The Green Book 2004. http://greenbook.treasury.gov.uk/.
28. Johnsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlof B, LIFE Study Group. Cost effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for Sweden of the LIFE trial. J Hypertens 2005; 23: 1425-1431.
29. Johannesson M, Dahlof B, Lindholm LH, Ekbom T, Hansson L, Oden A et al. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234: 317-323.
30. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 960-965.
31. Johannesson M, Johsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-336.
32. Jönsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: Results from the 4S trial. Diabetologia 1999; 42: 1293-1301.
33. Towse A, Pritchard C. Does NICE have a threshold? An external view. In: Towse A, Pritchard C, Devlin N (eds). Cost-Effectiveness Thresholds. Economic and Ethical Issues. King's Fund and Office of Health Economics: London, 2002.
34. Eichler H-G, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-528.
35. Newhouse JP. US and UK health economics: Two disciplines separated by a common language? Health Econ 1998; 7(Suppl): S79-S92.
36. Kalra L, Evans A, Perez I, Knapp M, Donaldson N, Swift CG. Alternative strategies for stroke care: A prospective randomised controlled trial. Lancet 2000; 356: 894-899.
37. van Exel J, Koopmanschap MA, van Wijngaarden JDH, Scholte op Reimer WJM. Costs of stroke and stroke services: Determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. Cost Eff Resour Alloc 2003; 1: 2.
38. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459-1466.
39. Wolf-Maier K et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.
40. Dahlöf B et al. Population impact of losartan use on stroke in the European Union (EU: Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004; 18: 367-373.
41. Olsen P, Burgess E. The rationale for ARBs based on the LIFE Trial: A Canadian thought leader perspective from Ellen D, Burgess, MD, accessed from www.medscape.com/viewarticle/495395.